Pharmaceuticals News and Research

RSS

Novo Nordisk to use Trialbee's services for e-recruitment of patients for clinical studies

Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in important efficiency gains for the pharmaceutical company.

20 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.

20 Jan 2014

Queen's University Belfast scientists receive international recognition for research on microneedles

Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.

20 Jan 2014

Research provides important new information about transmission of human leishmaniasis

Research involving scientists at the University of York has provided important new information about transmission of human leishmaniasis, a group of infectious diseases which kills more than 100,000 people a year.

18 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Gene therapies correct three forms of retinal degenerative diseases

Gene therapies developed by University of Pennsylvania School of Veterinary Medicine researchers have worked to correct different forms of blindness. While effective, the downside to these approaches to vision rescue is that each disease requires its own form of gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.

17 Jan 2014

Hope in sight for sufferers of chronic renal disease

Miss M. spends around 15 hours a week in hospital. Her renal functions are limited, and her kidneys are no longer able to filter toxins from her blood. She is a dialysis patient, forced to rely on this artificial blood purification treatment that, although essential, greatly impairs her quality of life. She has to make three trips a week to the dialysis clinic and going away for longer than a few days is almost out of the question. And Miss M. is no exception: In Germany alone, over six million people suffer from some form of chronic renal disease.

17 Jan 2014

Heritage announces availability of Prochlorperazine Edisylate Injection

Heritage Pharmaceuticals Inc. announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength.

16 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding.

16 Jan 2014

RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Aqua Pharmaceuticals Holdings, Inc. to Almirall S.A. for up to $402.6 million in cash

16 Jan 2014

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.

16 Jan 2014

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

scar Fern-ndez-Capetillo's research group has developed compounds that only a few weeks ago were licensed by the Spanish National Cancer Research Centre (CNIO) to a pharmaceutical company for the creation of new anti-tumour drugs.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

Research identifies new way for slow release drugs

Reservoirs of pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for slow, concentrated delivery of drug treatments, according to new research published in ACS Macro Letters.

15 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury.

13 Jan 2014

Pharmaceuticals News and Research

Novo Nordisk to use Trialbee's services for e-recruitment of patients for clinical studies

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Queen's University Belfast scientists receive international recognition for research on microneedles

Research provides important new information about transmission of human leishmaniasis

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

FDA approves New Drug Application for PENNSA 2%

Gene therapies correct three forms of retinal degenerative diseases

Hope in sight for sufferers of chronic renal disease

Heritage announces availability of Prochlorperazine Edisylate Injection

Biothera enhances innate immune responses to Imprime PGG drug candidate

Prostate cancer vaccines receive a boost in funding

RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientist receives € 2M Consolidator Grant for creation of new anti-tumour drugs

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Research identifies new way for slow release drugs

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence